Pfizer pours $25m into Vedanta's Phase II IBD study 19-Jan-2021 By Jenni Spinner The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate.